A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 As an Epigenetic Modulator in Prostate Cancer Cells.

Chao Yang,Wanhe Wang,Jia-Xin Liang,Guodong Li,Kasipandi Vellaisamy,Chun-Yuen Wong,Dik-Lung Ma,Chung-Hang Leung
DOI: https://doi.org/10.1021/acs.jmedchem.7b00133
IF: 8.039
2017-01-01
Journal of Medicinal Chemistry
Abstract:We report herein a novel rhodium(III) complex 1 as a new LSD1 targeting agent and epigenetic modulator. Complex 1 disrupted the interaction of LSD1-H3K4me2 in human prostate carcinoma cells and enhanced the amplification of p21, FOXA2, and BMP2 gene promoters. Complex 1 was selective for LSD1 over other histone demethylases, such as KDM2b, KDM7, and MAO activities, and also showed antiproliferative activity toward human cancer cells. To date, complex 1 is the first metal-based inhibitor of LSD1 activity.
What problem does this paper attempt to address?